Adjuvant Therapies for Esophageal Cancer

Sung H. Ferlay J. Siegel R.L. et al.

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

CA Cancer J Clin. 71: 209-249National Cancer Institute Surveillance

Epidemiology, and End Results Program. Cancer stat facts: Esophageal cancer.

() ()Cummings L.C. Cooper G.S.

Descriptive epidemiology of esophageal carcinoma in the Ohio Cancer Registry.

Cancer Detect Prev. 32: 87-92Gavin A.T. Francisci S. Foschi R. et al.

Oesophageal cancer survival in Europe: a EUROCARE-4 study.

Cancer Epidemiol. 36: 505-512Uhlenhopp D.J. Then E.O. Sunkara T. et al.

Epidemiology of esophageal cancer: update in global trends, etiology and risk factors.

Clin J Gastroenterol. 13: 1010-1021

Esophageal cancer: epidemiology, pathogenesis and prevention.

Nat Clin Pract Gastroenterol Hepatol. 5: 517-526Blot W.J. Devesa S.S. Fraumeni Jr., J.F.

Continuing climb in rates of esophageal adenocarcinoma: an update.

Jama. 270: 1320

Esophageal cancer.

N Engl J Med. 349: 2241-2252Al-Batran S.E. Homann N. Pauligk C. et al.

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.

Lancet (London, England). 393: 1948-1957Reynolds J.V. Preston S.R. O'Neill B. et al.

Neo-AEGIS (Neoadjuvant trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (Modified MAGIC or FLOT protocol). (NCT01726452).

J Clin Oncol. 39: 4004van Hagen P. Hulshof M.C. van Lanschot J.J. et al.

Preoperative chemoradiotherapy for esophageal or junctional cancer.

N Engl J Med. 366: 2074-2084Macdonald J.S. Smalley S.R. Benedetti J. et al.

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.

N Engl J Med. 345: 725-730Fuchs C.S. Niedzwiecki D. Mamon H.J. et al.

Adjuvant chemoradiotherapy with epirubicin, cisplatin, and fluorouracil compared with adjuvant chemoradiotherapy with fluorouracil and leucovorin after curative resection of gastric cancer: results from CALGB 80101 (Alliance).

J Clin Oncol. 35: 3671-3677Dikken J.L. Jansen E.P. Cats A. et al.

Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer.

J Clin Oncol. 28: 2430-2436Park S.H. Lim D.H. Sohn T.S. et al.

A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial(☆).

Ann Oncol. 32: 368-374Sakuramoto S. Sasako M. Yamaguchi T. et al.

Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.

N Engl J Med. 357: 1810-1820Sasako M. Sakuramoto S. Katai H. et al.

Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer.

J Clin Oncol. 29: 4387-4393Bang Y.J. Kim Y.W. Yang H.K. et al.

Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.

Lancet. 379: 315-321Armanios M. Xu R. Forastiere A.A. et al.

Adjuvant chemotherapy for resected adenocarcinoma of the esophagus, gastro-esophageal junction, and cardia: phase II trial (E8296) of the Eastern Cooperative Oncology Group.

J Clin Oncol. 22: 4495-4499Zhang X. Liang H. Li Z. et al.

Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial.

Lancet Oncol. 22: 1081-1092

Clinical Practice Guidelines in Oncology - Esophageal and Esophagogastric Junction Cancer.

() ()Cunningham D. Allum W.H. Stenning S.P. et al.

Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer.

New Engl J Med. 355: 11-20Ychou M. Boige V. Pignon J.P. et al.

Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.

J Clin Oncol : official J Am Soc Clin Oncol. 29: 1715-1721Hsu P.K. Huang C.S. Wang B.Y. et al.

Survival benefits of postoperative chemoradiation for lymph node-positive esophageal squamous cell carcinoma.

Ann Thorac Surg. 97: 1734-1741Ni W. Yu S. Xiao Z. et al.

Postoperative adjuvant therapy versus surgery alone for stage IIB–III Esophageal squamous cell carcinoma: a phase III randomized controlled trial.

Oncologist. 26: e2151-e2160Pouliquen X. Levard H. Hay J.M. et al.

5-Fluorouracil and cisplatin therapy after palliative surgical resection of squamous cell carcinoma of the esophagus. A multicenter randomized trial. French Associations for Surgical Research.

Ann Surg. 223: 127-133Ando N. Iizuka T. Kakegawa T. et al.

A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study.

J Thorac Cardiovasc Surg. 114: 205-209Ando N. Iizuka T. Ide H. et al.

Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204.

J Clin Oncol. 21: 4592-4596Heroor A. Fujita H. Sueyoshi S. et al.

Adjuvant chemotherapy after radical resection of squamous cell carcinoma in the thoracic esophagus: who benefits? A retrospective study.

Dig Surg. 20 (): 229-235Ténière P. Hay J.M. Fingerhut A. et al.

Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. French University Association for Surgical Research.

Surg Gynecol Obstet. 173: 123-130Fok M. Sham J.S.T. Choy D. et al.

Postoperative radiotherapy for carcinoma of the esophagus: a prospective, randomized controlled study.

Surgery. 113: 138-147Xiao Z.F. Yang Z.Y. Liang J. et al.

Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients.

Ann Thorac Surg. 75: 331-336Malthaner R.A. Wong R.K. Rumble R.B. et al.

Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a clinical practice guideline.

BMC cancer. 4: 67Lin H.N. Chen L.Q. Shang Q.X. et al.

A meta-analysis on surgery with or without postoperative radiotherapy to treat squamous cell esophageal carcinoma.

Int J Surg. 80: 184-191Tepper J. Krasna M.J. Niedzwiecki D. et al.

Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.

J Clin Oncol. 26: 1086-1092Gebski V. Burmeister B. Smithers B.M. et al.

Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.

Lancet Oncol. 8: 226-234Oppedijk V. van der Gaast A. van Lanschot J.J. et al.

Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials.

J Clin Oncol : official J Am Soc Clin Oncol. 32: 385-391Kelly R.J. Ajani J.A. Kuzdzal J. et al.

Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer.

New Engl J Med. 384: 1191-1203

留言 (0)

沒有登入
gif